PubMed=8180967; DOI=10.1016/0304-3835(94)90029-9
Cinatl J. Jr., Cinatl J., Hernaiz Driever P., Rabenau H.F., Novak M., Benda R., Gumbel H.O.C., Kornhuber B., Doerr H.-W.
Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate.
Cancer Lett. 78:41-48(1994)

PubMed=12670897
Cinatl J. Jr., Cinatl J., Michaelis M., Kabickova H., Kotchetkov R., Vogel J.-U., Doerr H.-W., Klingebiel T., Hernaiz Driever P.
Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
Cancer Res. 63:1508-1514(2003)

PubMed=23882450; DOI=10.3389/fonc.2013.00183; PMCID=PMC3713458
Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G., Linardic C.M.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183.1-183.12(2013)

PubMed=23665679; DOI=10.1038/onc.2013.129
Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Oncogene 33:1877-1889(2014)

PubMed=25749379; DOI=10.18632/oncotarget.2889; PMCID=PMC4627332
Michaelis M., Rothweiler F., Loschmann N., Sharifi M., Ghafourian T., Cinatl J. Jr.
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.
Oncotarget 6:17605-17620(2015)